The first day of the year is a time for personal reflection: Where did last year go? Why have I so many unfinished projects? Did I really drink that much champagne last night? It’s also a time to reflect on the last year of Alzheimer’s disease research. To help with the last item, we sifted through our news coverage and consulted scientific advisors. Here we offer you a list of notable 2010 developments and of trends to watch in 2011 and beyond. The list is by no means exhaustive, but we hope offers an idea of the key questions researchers are addressing. Did we miss anything? What stood out in your mind? Nominate your own favorites in the comment box below.

1. Funding Focus
The year started and finished with dismal news on research funding. In January, The Journal of the American Medical Association reported that, though biomedical research funding had doubled between 1998 and 2003, it fell by 2 percent in 2008. By November, it was apparent that the National Institute on Aging was facing a crisis that shocked AD researchers: The NIA pay line for the next fiscal year could be as low as 3 percent. There was some good news as various groups rallied to support research. Funding was found for ADNI2, the second phase of the Alzheimer’s Disease Neuroimaging Initiative, researchers jointly pulled off the Breakthrough Ride in support of better funding and two bills that were languishing in Congress, and one of those bills, the National Alzheimer’s Project Act, is likely to be enacted following successful passage in December through both houses of Congress.

2. Trials and Tribulations
Alzheimer’s drug development continues to struggle mightily. Dimebon looked good—too good to be true, perhaps—in a Phase 2 trial for Alzheimer’s and one for Huntington’s disease in early 2010, but in a Phase 3 trial, AD patients on Dimebon benefited none whatsoever. Later, the field was stunned when Eli Lilly’s Phase 3 trial of the γ-secretase inhibitor Semagacestat ended prematurely because patients taking the drug did worse cognitively than did those on placebo. Rosiglitazone failed, as did DHA. There were some glimmers of hope. Amyloid imaging showed that passive immunization with Bapineuzumab, a humanized monoclonal antibody, lowers amyloid in the brain. A small Phase 2 trial suggested that a mixture of human immunoglobulins given intravenously can slow clinical decline and brain atrophy in people with AD. A nicotinic receptor agonist is looking good in Phase 2 so far, and intranasal insulin showed some promise as well. Numerous trials are recruiting. On the "better trials" front, near perfect correlation between binding of Avid Pharmaceutical’s amyloid ligand florbetapir (AV-45) and postmortem plaque analysis seemed to put the ligand on the fast track for regulatory approval, and a pharma/academic/government coalition is developing shared tools for all to improve the process. What do you think—hopeful time? Disheartening time?

3. Promoting Prevention, First in Familial Disease
The trial failures have intensified the field’s desire to test whether in AD, an ounce of prevention indeed is worth a pound of cure. Hopes that an intervention could be found to delay onset of AD got a boost from the Alzheimer’s Prevention Initiative, which convenes leaders in academia, industry, philanthropy, and the regulatory agencies to brainstorm prevention strategies, initially for familial disease. For its part, the Dominantly Inherited Alzheimer Network (DIAN) is enrolling for a six-year study to monitor clinical development of disease from as early as 20 years prior to predicted clinical onset. Spurred by DIAN, the European Medicines Agency hosted an international meeting in London to discuss prevention and therapy trials in families with autosomal-dominant AD, a group that has long been ignored by trialists. These initiatives tackling prevention research in a new way took on even greater significance when an independent expert NIH panel proclaimed that current evidence on prevention in the general population is too weak to warrant any public health recommendations on measures to head off AD. Do you agree that prevention research is the way to go? How would do it?

4. Revised Diagnostic Criteria
Almost as controversial as the NIH expert panel’s verdict on the strength of current prevention data was the call for revised diagnostic criteria for AD, which were proposed in draft form at the International Conference on Alzheimer’s Disease last July. A majority of researchers and clinicians welcomed the new research criteria, which aim to diagnose years earlier with the help of cognitive testing and biomarkers, but there were detractors as well. Where are you on that one?

5. Biomarkers
Biomarkers enjoy exponential growth in interest. Researchers in Japan reported a potential diagnostic test for large Aβ oligomers; some colleagues called this a breakthrough provided others can replicate it. In general, scientists pushed toward finding markers that pop up earlier and earlier in disease progression. Researchers are increasingly focusing on cognitively normal individuals to search for factors that predispose to dementia. Proteomics platforms are broadening the range of potential plasma markers. Olfactory failure emerged as an early but non-specific marker. What does your nose tell you about where this field is headed?

6. ApoE
As ApoE continues to dominate as a risk factor for AD, human evidence grows that it can disturb brain networks even before Aβ can be detected in the brain. Researchers continue to wrestle with how the ApoE4 allele leads to AD, however, with the latest data suggesting that it has local synaptic effects. ApoE receptors and receptor ligands emerged as key mediators of synaptic plasticity. What has you most excited about this perennial but elusive player in AD?

7. Genetics
The question of whether ApoE itself or the adjacent gene Tomm40 puts people at risk continues to be debated. Meanwhile, new genetic risk factors emerged from genomewide association studies, and they held up in replication studies, quickly jumping into the AlzGene Top Results. Genotyping data from ADNI uncovered an obesity gene as a potential risk factor, and genetic variants were found that modulate cerebrospinal fluid levels of tau. The trend here is to mine biomarker datasets against genotyping information to fish out endophenotypes. On a historical note, researchers reported that they have likely pinned down the mutation carried by Auguste D., Alois Alzheimer’s most famous patient, and it happens to be the one that today plagues the Volga Germans, a large pedigree of U.S. citizens, some of whom participate in DIAN, others of whom advocate for more AD research funding in Congress. On a technical note, exome sequencing is the trend to watch in human genetics. What did we miss? Let us know.

8. Aβ Machinations
Aβ continues to claim the lion’s share of research studies. Advances were made in understanding its production, aggregation, function, and toxicity. Perhaps most striking was a human study showing that people with AD don't produce more Aβ but clear it more slowly. A γ-secretase-activating protein that specifically modulates APP processing made a splash, as did the provocative finding that Aβ planted in the periphery could seed amyloidosis in mouse brain. A new mouse model also hints that Aβ can spread from one area of the brain to another via synaptic connections. Soluble oligomers continued to dominate as the most toxic forms of the peptide and were shown to track with dementia severity. Did we skip an important paper?

9. Tau Trouble
The link between the two hallmarks of AD, Aβ plaques and tau-laden neurofibrillary tangles, has long perplexed researchers. In 2010, the link between tau and Aβ synaptic toxicity grew stronger with the twin findings that tau ferries Fyn kinase to the synapse, where it can mediate Aβ-induced excitotoxicity, and that tau mediates Aβ’s toxic tweaking of axonal transport. Therapies aimed at tau oligomers are at the mouse stage. What intrigued you the most about tau last year?

10. Gamma-Secretase Structure and Function
The complexity of γ-secretase makes it a tough molecule to study. This year, researchers succeeded in reconstituting γ-secretase activity using only presenilin-1 (PS1) and liposomes. Researchers made advances in figuring out the structure and function of PS1 even as a complex, which could aid design of better γ-secretase inhibitors. But questions about pleiotropism persist, with more evidence that the mysterious endoplasmic reticulum calcium leak channels are made up of presenilins. Does this work make γ-secretase a safer target?

11. Metals and AD
The relationship between metals and AD continually resurfaces, but not in the sense of aluminum leaching from your pots and pans. No, iron and zinc were the dominant metals this year. Researchers reported that mice lacking a zinc transporter develop symptoms that uncannily resemble AD, and that the amyloid precursor protein acts as an iron transporter. Shifting iron out of the brain could be beneficial, because older primates on a calorie-restricted diet have less iron in the brain and better synaptic activity and motor skills. Prana's PBT-2 drug is set to begin a phase 2b trial in 2011.

12. Stem Cells
Stem cell therapy for AD may be a pipe dream, but the cells have plenty of uses. Researchers improved methods for making induced pluripotent stem cells, and for converting them into neurons that could reveal individual susceptibility to a variety of neurodegenerative diseases.

13. Glia
Finally, it is not always about neurons. Glia keep the brain ship-shape not only when neurodegenerative storm clouds gather. Researchers reported this year that microglia prune healthy synapses, which came as something of a surprise. In other glial news, knocking out glial cross-communication via chemokines actually prevents neuron loss in mouse models of AD. In contrast, microglial migration fueled by noradrenaline from the locus ceruleus seems to protect against Aβ toxicity. The great good-versus-evil debate on the nature of microglia continues at least into 2011. What is your take?—Tom Fagan.


  1. The year 2010 was a very important one for presenilin research and involved a number of (in my opinion) revolutionary papers that advanced our understanding of how presenilin-1 (PSEN1) and PSEN2 can contribute to Alzheimer's disease. The harvest actually began in late 2009 with a simple and elegant paper from Eric Schon's lab, showing that the presenilins, APP, and γ-secretase activity appear to be concentrated in a specialized portion of the endoplasmic reticulum, the mitochondria-associated membranes, where we can find many other well-known partners of the presenilins and where regulation of calcium ion flow is especially important. These data strongly support a central role of mitochondria and energy production/oxidative stress in AD (Area-Gomez et al., 2009).

    A later 2010 paper in the Journal of Alzheimer's Disease by Schon and Area-Gomez explained why previous immunohistochemistry analyses had not seen this subcellular localization.

    Another very important paper was that by Lee et al. (Lee et al., 2010; see also ARF related news story) showing that PSEN1 holoprotein is required for autophagy and autolysosome acidification, and that FAD mutations hamper this function. This raises questions about the relative importance of Aβ40:42 ratios (and, indeed, even γ-secretase activity) in AD pathogenesis, and may explain why presenilin proteins can be found in organisms in which no γ-secretase activity is said to exist. This work emphasizes the importance of understanding the effect of the 180+ FAD mutations in PSEN1 on the non-γ-secretase functions of this protein—a topic which has previously received relatively very little attention.

    I was also fascinated by the 2010 paper by Gama Sosa et al. (Gama Sosa et al., 2010) showing that FAD mutant PSEN1 protein expressed only in transgenic mouse neurons could, nevertheless, have dramatic effects on brain microvasculature, which gives added weight to arguments that changes in vascular function are very important in AD.


    . Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Am J Pathol. 2009 Nov;175(5):1810-6. PubMed.

    . Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 2010 Jun 25;141(7):1146-58. PubMed.

    . Age-related vascular pathology in transgenic mice expressing presenilin 1-associated familial Alzheimer's disease mutations. Am J Pathol. 2010 Jan;176(1):353-68. PubMed.

  2. While scientists and researchers celebrate a number of revolutionary research findings and papers that advance our understanding of how genetics, and biological and risk factors contribute to Alzheimer's disease, more resources should be poured into dementia care and family-centered research and services. Some limitations of recent family studies in dementia care include: the paucity of clinical trials with comprehensive education; skill training and supportive interventions; a broad range of outcome measures; sufficient study power; poor adherence to treatment protocols; and underestimation of clients’ problem behaviors and caregivers’ health needs (Belle et al., 2006; Brodaty et al., 2003).

    Among a few potentially effective intervention approaches, a multi-component educational and supportive program may be an effective one in responding to the complexity and varying levels of needs and difficulties in dementia care (Brodaty et al., 2003). The intervention should involve multiple strategies, such as education, problem-solving skills training, social support, and stress management techniques for enhancing caregivers’ knowledge and skills in dementia care. Some of these approaches also significantly impacted caregivers’ ability to deal with clients’ behavioral problems, but few improved family caregivers’ health condition or mental well being. To address the gaps in quality of care for people with dementia and their caregivers, a new community-based family support program in dementia care should be developed to enhance caregivers’ quality of life, offer social support, ease their burden, and to address patient symptoms and rates of institutionalization.


    . Enhancing the quality of life of dementia caregivers from different ethnic or racial groups: a randomized, controlled trial. Ann Intern Med. 2006 Nov 21;145(10):727-38. PubMed.

    . Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc. 2003 May;51(5):657-64. PubMed.

  3. I would add No. 14. Membrane trafficking.

    In 2010, more building blocks were added to consolidate the hypothesis that abnormalities in APP trafficking is at the root of Alzheimer’s disease (AD) pathology, including aberrant APP processing, intraneuronal Aβ accumulation, increased expression of active GSK3β, altered neurotrophic signaling, and cholinergic neuron degeneration.

    Abnormal membrane trafficking, a well-known early hallmark of both AD and Down's syndrome, is APP dose dependent, is accompanied by an increase in Rab5 activity, precedes soluble parenchymal Aβ40-42 rise, and renders neurons susceptible to AD cytoskeletal pathology (Cataldo et al., 1996, Cataldo et al., 2003, Grbovic 2003).

    During the summer, Ginsberg et al. reported that the postmortem brains of patients affected with cognitive decline display a selective increase of Rab5 and Rab7 proteins in regions vulnerable to AD pathology. Only Rab5 levels correlated with disease progression in the basal forebrain and hippocampus (Ginsberg et al., 2010b). The same lab also provided data pointing to a causal link between an increase in Rab5 and the downregulation of the BDNF receptors at both protein and expression levels implicating Rab5 in TrkB-induced cell survival (Ginsberg et al., 2010a).

    I also found it interesting that γ-secretase inhibition or the overexpression of the 99C-GFP fragment were both able to enlarge and increase the number of early endosome antigen 1-positive endosomes in normal human fibroblasts, partially mimicking the effect of APP overexpression. This suggests that the C-terminal transmembrane fragment 99C might play a critical role in triggering the abnormal AD endocytic phenotype (Jiang et al., 2010 and ARF related news story).

    In August 2010, Akira Sawa, Tracy Young-Pearse, and colleagues showed that APP interacts with the product of the schizophrenia susceptibility gene DISC1 through its intracellular domain (APP residues 666-680; see Young-Pearse et al., 2010). In November, at the Society for Neuroscience meeting in San Diego, Zoia Muresan reported that both DISC1 and its interactor kinesin 1 are involved in the anterograde transport of APP. In the R1.40 AD murine YAC model, this group observed an increased level of DISC1 in brain regions showing amyloid plaques, and DISC1 was found in both intracellular and extracellular Aβ deposits. Depletion of DISC1 prevented the transport and intracellular Aβ accumulation in neurites of CATH.a differentiated cells (Muresan et al., 2006) by 90 percent. As far as I remember, the processing of Aβ was not affected, but the level of Aβ accumulation in the cells was undetectable.

    DISC1 is a scaffold protein involved in the spatial regulation of signaling, trafficking, and plasticity events in the brain. In particular, it is involved in the intracellular transport of various cargoes, including vesicles and organelles (Atkin et al., 2010, Shinoda, 2007). It is noteworthy that the subcellular distribution or level of some known DISC1 interactors is modified in AD and can interfere with APP processing and clearance (Camargo et al., 2007, Okada et al., 2010, Raychaudhuri et al., 2010).

    In my view, 2010 was a year where the role of the cognition-related gene DISC1 was first felt to spread well beyond schizophrenia. Hopefully, novel AD therapeutic targets will emerge from these membrane trafficking studies.


    . Disrupted in Schizophrenia-1 regulates intracellular trafficking of mitochondria in neurons. Mol Psychiatry. 2011 Feb;16(2):122-4, 121. PubMed.

    . Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol Psychiatry. 2007 Jan;12(1):74-86. PubMed.

    . Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease. J Neurosci. 1996 Jan;16(1):186-99. PubMed.

    . App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J Neurosci. 2003 Jul 30;23(17):6788-92. PubMed.

    . Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol Psychiatry. 2010 Nov 15;68(10):885-93. Epub 2010 Jul 23 PubMed.

    . Regional selectivity of rab5 and rab7 protein upregulation in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2010;22(2):631-9. PubMed.

    . Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. J Biol Chem. 2003 Aug 15;278(33):31261-8. PubMed.

    . Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1630-5. Epub 2009 Dec 28 PubMed.

    . Neuritic deposits of amyloid-beta peptide in a subpopulation of central nervous system-derived neuronal cells. Mol Cell Biol. 2006 Jul;26(13):4982-97. PubMed.

    . Proteomic identification of sorting nexin 6 as a negative regulator of BACE1-mediated APP processing. FASEB J. 2010 Aug;24(8):2783-94. PubMed.

    . DISC1 regulates neurotrophin-induced axon elongation via interaction with Grb2. J Neurosci. 2007 Jan 3;27(1):4-14. PubMed.

    . Grb2-mediated alteration in the trafficking of AbetaPP: insights from Grb2-AICD interaction. J Alzheimers Dis. 2010;20(1):275-92. PubMed.

    . Biochemical and functional interaction of disrupted-in-schizophrenia 1 and amyloid precursor protein regulates neuronal migration during mammalian cortical development. J Neurosci. 2010 Aug 4;30(31):10431-40. PubMed.

  4. We believe there is more than one right answer to the question, What is AD? Maybe what we are missing is to combine all the correct answers under one roof. When I look at this article, I see that 10 out of 13 titles are related to one of our research interests—the role of vitamin D (neurosteroid D) in AD and neurodegeneration. We believe a candidate molecule for treating or preventing AD should promote survival and detoxification of neurons, regulate the immune system, and have the potential to induce key intercellular signaling pathways. We thought that candidate should be vitamin D.

    We showed that polymorphism in the vitamin D receptor (VDR) gene may increase the vulnerability of people to AD by 2.3-fold (Gezen-Ak et al., 2007). Those findings were supported with a genomewide association study (GWAS) (Beecham et al., 2009). Additionally, associations between VDR polymorphisms, age-dependent cognitive decline, and insufficient serum levels of the precursor form of vitamin D (25 hydroxyvitamin D3) in AD patients and elderly people with cognitive decline were reported (Kunningas et al., 2009; Wilkins et al., 2006; Llewellyn et al., 2009; Llewellyn et al., 2010; Annweiler et al., 2010). Surprisingly, the results of our recent study indicated that amyloid-β (Aβ) treatment eliminated VDR expression in cortical neurons in addition to inducing L-type voltage sensitive calcium channels LVSCC-A1C and nerve growth factor production. Thus, we speculated that some of the toxic effects of Aβ might depend on vitamin D deficiency and/or insufficient utilization of vitamin D due to VDR protein depletion by Aβ (Dursun et al., 2010).

    The prevention of Aβ toxicity by vitamin D treatment, and the understanding of how Aβ effects vitamin D related pathways, might open up new frontiers in clarifying molecular mechanisms of neurodegeneration and provide a basis for novel perspectives in both preventing and treating Alzheimer’s disease.


    . Association between vitamin D receptor gene polymorphism and Alzheimer's disease. Tohoku J Exp Med. 2007 Jul;212(3):275-82. PubMed.

    . Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet. 2009 Jan;84(1):35-43. PubMed.

    . VDR gene variants associate with cognitive function and depressive symptoms in old age. Neurobiol Aging. 2009 Mar;30(3):466-73. PubMed.

    . Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry. 2006 Dec;14(12):1032-40. PubMed.

    . Serum 25-hydroxyvitamin D concentration and cognitive impairment. J Geriatr Psychiatry Neurol. 2009 Sep;22(3):188-95. PubMed.

    . Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med. 2010 Jul 12;170(13):1135-41. PubMed.

    . Association of vitamin D deficiency with cognitive impairment in older women: cross-sectional study. Neurology. 2010 Jan 5;74(1):27-32. PubMed.

    . A novel perspective for Alzheimer's disease: vitamin D receptor suppression by amyloid-β and preventing the amyloid-β induced alterations by vitamin D in cortical neurons. J Alzheimers Dis. 2011;23(2):207-19. PubMed.

Make a Comment

To make a comment you must login or register.


News Citations

  1. Research Brief: Announcing ADNI2—Funding for Five More Years
  2. World Alzheimer Report: Care Costs 1.0 Percent of World GDP
  3. Dimebon for HD—A Hint of Cognitive Benefit?
  4. Dimebon Disappoints in Phase 3 Trial
  5. Lilly Halts IDENTITY Trials as Patients Worsen on Secretase Inhibitor
  6. Trial Updates: B Vitamin Back in Vogue? Diabetes Drug Less Sweet
  7. Paper Alert: Negative DHA Trial Fuels Soul-Searching in AD Field
  8. PIB-PET Biomarker Study Confirms Bapineuzumab Lowers Amyloid
  9. Toronto: In Small Trial, IVIg Slows Brain Shrinkage
  10. Honolulu: Intranasal Insulin Trial Claims Promise in MCI, AD
  11. Toulouse: Experimental Drug Sensitizes Receptor, Boosts Cognition
  12. Honolulu: FDA Approval in Sight for 18F Amyloid Tracer Florbetapir?
  13. DC: CAMD Convenes Stakeholders to Reform Alzheimer’s Trials
  14. DIAN Dispatch From Hawaii: After Slow Start, Network Is Humming
  15. London: Europe-U.S. Regulators Mull Prevention Trial in Familial AD
  16. Noisy Response Greets Revised Diagnostic Criteria for AD
  17. Revised Criteria for Preclinical AD, Exactly as Presented
  18. What Do Clinicians Say? Peers Welcome Revised Criteria
  19. A Diagnostic Test for Large Aβ Oligomers?
  20. CSF Biomarkers Track With Atrophy, Cognition in Normal Aging
  21. ApoE2 Carriers Have Less Brain Atrophy, AD Pathology in Spinal Fluid
  22. ApoE and Brain Networks—The Anatomy of a Risk Factor
  23. San Diego: Pre-AD Brain Changes May Allow Early Diagnosis
  24. Blunted Sense of Smell Parallels Pathology in AD, PD
  25. A Foreshadowing? ApoE4 Disrupts Brain Connectivity in Absence of Aβ
  26. San Diego: ApoE, Aβ, and AD—Strengthening the Synaptic Connection
  27. San Diego: Aβ Oligomers Seen, With ApoE, at Synapses of Human Brain
  28. St. Louis: ApoE Receptors—Hold Sway Over Synaptic Function
  29. Research Brief: Reelin Loss Ramps Up Aβ Pathology
  30. Honolulu: Tomm40 Reported to Track With Brain Atrophy, Cognition
  31. Genetics of FTD: New Gene, PGRN Variety, and a Bit of FUS
  32. Toronto: 6th Sense—GWAS Picks Up New AD Risk Variant
  33. Repeat Offenders—CLU, CR1, PICALM Hold Up in Association Studies
  34. LOADing Up—Largest GWAS to Date Confirms Two, Adds Two Risk Genes
  35. Research Brief: Clusterin Grabs Spotlight Among Elite Few LOAD Genes
  36. Obesity Gene Depletes Brain Reserves, May Raise Alzheimer’s Risk
  37. Tau Timing: New Findings on Disease Progression, Clearance
  38. Research Brief: Auguste D.'s Mutation Identified?
  39. There’s a GSAP for That: Novel APP Partner a New Therapeutic Target?
  40. Sweet 16: Novel APP Processing Pathway and a New Biomarker?
  41. Quantum Leap? Nanoprobes Track Aβ Aggregation in Real Time
  42. Stable Aβ Oligomers?—A Little Protein Engineering Goes a Long Way
  43. Aβ Neurotoxicity—Is it the Dimer? No, and Yes
  44. San Diego: Flexible N-Termini Key to Aβ42 Oligomer Toxicity?
  45. Peripheral Aβ Seeds CAA and Parenchymal Amyloidosis
  46. Insidious Spread of Aβ: More Support for Synaptic Transmission
  47. New APP Model: No Plaques—Plenty of Pathology
  48. Aβ—Made Globally, Acts Locally
  49. New Paths to Protect Synapses From Aβ?
  50. Aβ Downs EphB2 Kinase, Disrupts Glutamate Receptors
  51. Aβ Oligomers: A Fatal Attraction for Glutamate Receptors?
  52. Bad Guys—Aβ Oligomers Live Up to Reputation in Human Studies
  53. Honolulu: Wake-Up Call—Aβ Clearance, Not Production, Awry in AD
  54. Brain Aβ Patterns Linked to Brain Energy Metabolism
  55. Honolulu: The Missing Link? Tau Mediates Aβ Toxicity at Synapse
  56. The Plot Thickens: The Complicated Relationship of Tau and Aβ
  57. San Diego: The Future of AD—Can We Vaccinate?
  58. San Diego: Tau Oligomer Antibodies Relieve Motor Deficits in Mice
  59. Who’s on First? Multiphoton Imaging Suggests Caspases, Not Tangles
  60. Sole Perp—PS1 Alone Reconstitutes γ-Secretase Activity
  61. Divide and Conquer: Structure-Function Victory With Presenilin 1
  62. Research Brief: Presenilin Simplicity—Evidence for Autoproteolysis
  63. Perplexing Presenilins: New Evidence for Calcium Leak Channels
  64. Iron Export? New Role Links APP, Metals, to Oxidative Stress
  65. Think Zinc—Mice Missing Key Ion Transporter Develop AD-like Problems
  66. Aging Primates—Brain Iron Up, Motor Skills and Plastic Synapses Down
  67. Stem Cells Move In, Set Up Shop in Brain
  68. Research Brief: From Fibroblast to Neuron in One Easy Step
  69. Where in the World Are the iPS Cells?
  70. In Alzheimer Disease Research, iPS Cells Catch On Slowly
  71. Hereditary Diseases: A Natural Fit For iPSC Modeling
  72. Not So Fast: iPS Cells Have Potential Pitfalls
  73. No Rest for Microglia: These Immune Cells Manage Healthy Synapses
  74. Death by Glia?—Chemokine Receptor Nudges Neuron Loss in AD Mice
  75. Norepinephrine Fuels Microglial Migration, Aβ Phagocytosis
  76. Noradrenaline: Fueling Microglial Fight Against Aβ

Other Citations

  1. News Brief: Biomedical Funding Dips, AD Research Feels the Pinch

External Citations

  1. AlzGene Top Results

Further Reading

No Available Further Reading